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AIM OF THE STUDY 
To evaluate the Palliative Prognostic Score (Pap)and the Palliative Prognostic 
Index (PPI) in patients receiving palliative radiotherapy and /or palliative care.  
Primary Objective 
To compare the sensitivity, specificity and positive predictive values of the two 
scales in prognosticating 1 week, one month,   and three month survivals. The primary 
outcome was sensitivity and specificity for estimating 1 month survival. 
Secondary objectives  
1. 1.To document the median survivals of  patients classified into good, 
intermediate, and better  prognostic categories.   
2. To assess the sensitivity and specificity of Score B when clinician’s prediction 
of survival is added to the score (modified score B). (Is modified score B 
better than the original score B?)  
3. To assess the sensitivity and specificity of score A when laboratory tests are 
excluded from the scoring system (How accurate is a simpler score A?)  
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INTRODUCTION  
Physicians who are taking care of terminally ill patients are often confronted with 
a question like “Doctor, How long do i have?” from the patients . Prognostic information 
is important with regards to continuation of treatment which  associated with further 
morbidity ,financial burden to care takers,place of care ,timely referral to hospice or 
palliative care center,to mentally and spiritually prepare for an imminent death,other 
family and  social commitments. 
Accurate prediction of survival is necessary for clinical, organizational, and 
ethical reasons, in helping to avoid inappropriate therapies in vulnerable patients and, in 
providing appropriate interventions where there is likelihood of benefit. Patients and 
their families often request such information so that they can make treatment choices 
and set personal goals. 
If patients can be reliably identified who will die in the next few days irrespective 
of what is done to them, then burdensome, ineffective   overtreatment maybe avoidable.   
Likewise,   undertreatment   due to therapeutic nihilism in those with a good chance of 
survival may also be prevented [1]. The steering committee of the European Association 
for Palliative Care stated that prognostication of life expectancy is a significant clinical 
commitment for clinicians involved in oncology and palliative care and can be achieved 
by combining clinical experience and evidence from the literature. The committee 
recommended that using and communicating prognostic information should be part of a 
multidisciplinary palliative care approach. [2] 
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REVIEW OF LITERATURE 
CLINICIAN’S PREDICTION  OF  SURVIVAL  ( CPS). 
CPS is clinician’s estmate of the probable life expectancy of the patients based 
on his or her experience. However, reports on its accuracy are conflicting, Iiteratures 
has been demonstrated that the CPS can be considerably inaccurate and 
physicians are systematically over optimistic in their assessments- for example in a 
study the median clinician estimated survival was 75 days, but the median actual 
survival was 25 days [3]. The experience and specialty of the physician and the nature 
of the physician–patient relationship may be confounders for the accuracy of the CPS .A 
prospective study of CPS when making referrals to a U.S. hospice indicated academic 
oncologists were more accurate than community oncologists or family physicians; and 
more experienced physicians were more accurate. However, this increased accuracy 
was blunted if the relationship between the physician and patient was strong. This led 
the authors to suggest an experienced but uninvolved  specialist physician was likely to 
be the most accurate and might be requested for a prognostic ‘second opinion’ if an 
accurate prognosis was deemed essential (e.g., deciding to withdraw life sustaining 
treatment) [4]. Conversely,  Oxenham in a study on hospice patients reported that   
predicting survival in the last days of life needs  a close knowledge about patients which 
are easily gained by spending time with them  rather than depending solely  on  lab 
investigations.The accuracy  in predicting survival improves over a period  as there is 
increase in  knowledge regarding patients condition .In the later stage accuracy of the 
clinician was improved  and  among  the staff  the nursing auxillaries  were  most  
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accurate  in predicting the prognosis as they spend considerable time with the patients 
[5]. 
In a systematic review Glare et all found that  the  temporal  CPS  overestimated 
the actual survival (AS) by 45% near  to  with  in 1 week in only 25% cases.But there 
was  good correlation [6]. In a  systematic review by Vigano et al  the CPS proved to be 
predictive of the Actual Survival (AS) even though the magnitude of the association  
was  low [7],[8],[9],[10],[11]. In a study by Vigano A on 227 consecutive patients, the 
CPS was a strong, independent prognostic value at multivariate analysis [12].In a 
Canadian study the specificity  of the CPS for less than equal to 2 months,2-6 months 
and more than 6 months were 95%,51% and 81% respectively.But the sensitivity was  
31%,68% and 54% respectively. The positive predictive values (PPV) were 
74%,41%,60% and negative predictive values (NPV)were 75%,76% and 77% 
respectively.In this study there was high specificity for the first and third categories[13]. 
In a review of CPS characteristics based on five studies, estimated survival was higher 
than AS by a factor ranging from 1.2 to 4, with a percentage of error between 30% and 
78% and a rate of optimistic errors out of the total errors of 63% to 92% [12]. 
A study done   by Christakis et al found that only 20% of predictions were correct, 
with doctors overestimating survival by a factor of 5.3. This lower prognostic accuracy 
was correlated with a longer doctor–patient relationship   and a shorter time interval 
since last examination. The other reasons   could be ignorance of prognostic factors, 
refusal to accept that   patient is in the terminal stage of disease, optimistic prejudice, 
and a feeling of omnipotence [4].In a study by Maltoni etal with experienced oncologists, 
the CPS had a percentage of error of only 30%, with a good balance between 
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overoptimistic   and overpessimistic errors. The CPS obtained a higher prediction 
accuracy than   reported in earlier studies (correlation coefficient with actual survival = 
0.51) and than that obtained with KPS alone (correlation coefficient = 0.37)[10]. The 
CPS is a useful base for a prognostic estimate even though as a subjective estimate it 
is influenced by the doctor’s experience and   could be poorly reproducible and 
unsuitable for non palliative physicians and medical program managers [14].  
Two ways of improving the CPS have been   suggested [15]. 
1. Asking   care givers not previously involved with the patient to estimate 
survival to  overcome optimistic proclivity, in that survival predictions 
averaged across physicians are more accurate . 
2. Integration of the CPS with more objective and reproducible survival 
predictors that have emerged from multivariate analysis [15].  
Some studies shows that KPS has greater prognostic capability [16]. 
The modifications of the KPS have proved capable of a prognostic impact in a palliative 
setting: Palliative Performance Scale [17].The Performance Status has also shown a 
prognostic capacity in groups of patients eligible for phase I studies with advanced or 
metastatic cancer [18,19]. The KPS showed an increase in its prognostic capacity when 
integrated with   data concerning the presence of specific symptoms.KPS is a reliable 
tool to predict the the imminent death if is less than or equal   to 40. But also a high 
score does not mean a long   survival. The clinical prediction of survival is more 
accurate than KPS in estimating the life span of patients with advanced malignancy.In 
the study by Maltoni et al in 100 patients the CPS obtained a higher prediction accuracy 
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than the past studies with a correlation coefficient with actual survival=0.51 and that 
obtained with KPS alone; correlation coefficient =0.37.The median difference between 
predicted  and expected survival was only 1 week[10].  
PAP   SCORE 
A study  by  Marco Pirovano et al showed the construction of a simple prognostic 
score based on factors identified in a prospective multicenter study done in 22 centres 
in Italy. There were   519 patients with a median survival of 32 days who were 
diagnosed to have advanced solid tumours and were no longer  considered  suitable for 
primary treatment. They used an exponential multiple regression model and from an 
initial model with 36 variables, a final model was  created  by means of a backward 
selection procedure. There are six variables are found to be independent  predictors  of  
survival: Clinical Prediction of Survival (CPS), Karnofsky Performance Status (KPS), 
anorexia, dyspnea, total white blood count (WBC) and lymphocyte percentage. 
 
These variables were given a numerical score, based on the relative weight of 
the independent prognostic significance shown by each single category in the 
multivariate analysis. The sum of the single scores gives the overall PaP Score for each 
patient and it ranges from 0 to 17.5  .It  can subdivide the study population into three 
groups, each with a different probability of survival at 30 days: (1) group A: probability of 
survival at 30 days >70%, with patient score less than equal to 5.5; (2) group B: 
probability of survival at 30 days 30–70%, with patient score 5.6–11.0; and (3) group C: 
probability of survival at 30 days <30%, with patient score >11.0.Using this method, 
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178/519 (34.3%) patients were classified in risk group A, 205 (39.5%) patients were in 
risk group B, and 136 (26.2%) patients were in risk group C. The patients classified in 
the three risk groups had a very different survival experience (logrank=294.8,P<0.001), 
with a median survival of 64 days for group A, 32 days for group B, and 11days for 
group C. The PaP Score based on these simple variables were proved to be statistically 
significant in a multivariate analysis [8].  
A prospective study was conducted in Australia by Glare et al  to validate PaP 
score. They calculated individual PaP scores for 100 terminally ill patients (91% with 
known malignant disease and 9% with Non-cancer diagnosis).This was done in a 
palliative medicine consultation service based in a university teaching hospital.The PaP 
score was able to subdivide this patient population into 3 groups (A,B,C).The 
percentage survival at 30 days for the three groups were 66%,54%, and 5% 
respectively. These results showed that PaP was good at  predicting  the survival  for 
the poorest survival group ;but less at distinguishing between the good  and 
intermediate  groups.  
The PaP score depends on clinical prediction of survival (CPS) and this is a 
weakness of the PaP model.Major variations occur among the clinicians based on their 
experience and knowledge in the care of terminally ill patients. The ability is derived 
from the integration of other clinical data like knowledge of the natural history of 
disease, rate of progression, response to treatment, comorbidities and psychological 
issues.    But   CPS has unique role in PaP score in estimating the survival [1].  
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In another study by Glare et al the PaP score was validated   in 100 patients with 
advanced cancer under the care of a medical or radiation oncologist at a university 
teaching hospital in Australia. 
They used survival data from 98 patients. The overall median survival was 12 
weeks (interquartile range, 7 to 25 weeks). The PaP score divided the heterogeneous 
patient sample into three isoprognostic groups related to the chance of surviving 1 
month, with 64 patients in group A (> 70% chance), 32 patients in group B (30% to 70% 
chance), and four patients in group C (< 30% chance). The estimated median survival of 
the three groups was 17 weeks (95% CI, 12 to 26 weeks), 7 weeks (95% CI, 4 to 12 
weeks), and less than 1 week (95% CI, < 1 to 3 weeks), respectively. These survival 
differences were highly significant (log-rank test of trend, 12 = 25.65; P < .0001). The 1-
month survival of the groups was 97%, 59%, and 25%, respectively [20]. 
In a study by Maltoni  PaP score was calculated for  451 patients in  an Italian 
palliative care program. A scoring was   given and patients are subdivided into 3 specific 
risk groups based on the PaP risk variables. There was a training group and testing 
group.The median survival was 76 days in group A( with a 86.6 % probability of 30-day 
survival,32 days in group B( with a 51.6% probability  of 30 day survival), and 14 days in 
group C ( with a 16.9% probability of 30 day survival).  The survival medians for the 
trainset was also similar (64 days in group A, 32 days in groupB,and 11 days in 
groupC)[21]. 
In a study by Davide et al the PaP score was applied to 173 patients with 
advanced, pretreated gastrointestinal or nonsmall cell lung cancer before starting a 
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further line of palliative chemotherapy . Univariate   and multivariate analysis of survival 
was performed using the logrank   test, the Cox regression model respectively. 
Symptom distress scores   were   compared   using multivariate analysis of variance 
test for repeated measures, and overall symptom distress score was compared using 
analysis of variance test for repeated measures. The overall median survival was 26 
weeks; in PaP score class A it was 32 weeks, and in class B 8 weeks (p<0.0001). No 
patient was classified in class C. The two-class PaP score resulted in an independent 
prognostic factor (p=0.022), as well as Karnofsky performance status (p=0.002)and 
colorectal cancer (p=0.017). A trend towards worsening of symptom distress was 
observed in the entire population and in class A. It showed that the PaP  score   can  
predict  patients who could benefit by palliative chemotherapy  from  those  who benefit 
by supportive and palliative care. But the data were insufficient to validate the use of the 
PaP score in patients to be treated with palliative chemotherapy. They advised further 
trials to validate the usefullnes of PaP in this setting of selecting patients for palliative 
chemotherapy [22]. 
PALLIATIVE PROGNOSTIC INDEX 
Morita et al  analysed the data  on performance status and the presence or 
absence of 21 symptoms in    150 patients admitted in a hospice .They  identified  5 
variables like performance status, oral intake ,oedema, dyspnoea  at rest and delirium  
as independent predictors of  survival and each variable are given a partial score. A  
sum of the partial scores of these variable  ranged from 0 to 15.The patients were 
grouped in to three depending on their PPI score( group A,PPI less than or equal to 
2;group B more than 2but less than 4;group C with a PPI of more than 4).Using  the 
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score >4 was taken as a cut-off ,a 6 week survival was predicted with a positive 
predictive value of  0.86 and a negative predictive value of  0.70.This  PPI  was then 
tested in an Independent  cohort of 95 patients and the predictive value of the scoring 
system was  confirmed, for patients  with a PPI score >4,6 week survival was predicted 
with PPV of 0.83 and NPV of 0.71[23]. 
In another study by Morita et al   by 2 independent  series  of of hospice patients 
were studied(n= 150 and 108).He studied whether clinical prediction of survival (CPS) 
can be improved using PPI . In the first study, the CPS was prospectively recorded 
by primary physicians on the basis of their clinical experiences.  In the second study, 
physicians estimated patient prognoses with a reference to the PPI score. The cases 
where the differences between actual survival (AS) and CPS were 28 days or longer 
significantly decreased in the second study compared to the first study (42% vs 23%, P 
< 0.01). Also, the cases where AS was either twice longer or half shorter than CPS 
significantly declined (49% vs 37%, P= 0.050). ). As well, serious errors, defined as the 
cases where AS was either (a) 28 days and twice longer than CPS or (b) 28 days and 
half shorter than CPS, were also significantly decreased from 27% in the first study 
group to 16% in the second study group (P = 0.028).The PPI was found to predict 6 
week survival with a PPV of 0.91 and NPV of 0.67[24, 25]. In  another  study by Stone 
et al PPI was validated .The study population included patients receiving palliative 
chemotherapy and radiotherapy.The  patients  were  included in a hospital –based 
consultancy  palliative  care service , a hospice home care service and a hospice 
inpatient unit. There were a total of 194 patients  and 43% of the patients  were 
receiving chemotherapy/or radiotherapy or both. The  patients were divided into 3 risk 
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groups based on the  PPI score.Group  I  corresponded to PPI less than or equal 
to4,median survival was 68 days(95% confidence interval[CI]52,115 days).Group 2 
corresponded to those with  PPI more than 4 but less than equal to 6,median survival 
was 21 days(95% CI 13,33), and group 3 corresponded to patients  with PPI more than 
6 ,median survival was 5 days(95% CI 3,11).In  this  study  survival of less than 3 weeks 
was predicted with a positive predictive value of  86% and negative predictive value  of 
76 %.Survival less than 6 weeks was predicted with a positive predictive value of  91% 
and negative predictive value of  64%.The  PPI was quick and easy to use and it can be 
applied in hospital based,home based or hospice based  patients [26]. 
In a recent study from Germany by Stiel et al PPI, PaP-S and physicians’ 
estimations were compared in survival predictions in 83 patients. The correlations 
between survival time and the prognostic scores or physicians’ prognosis were lower. 
The physicians’ estimations overestimated survival time on average fourfold. The 
estimations were more or less correct for the good and bad prognosis groups. None of 
the prognostic scores could show a precise reliable prognostic estimate for the 
individual patient. But scores were helpful for ethical decision making and team 
discussions. They opine that estimating survival time from clinical experience seems to 
be easier and practical in the 2 extreme groups (very good vs very bad prognosis).The 
limitation of this study was its small sample size (83) patients [27].   
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MATERIALS AND METHODS 
This was an observational cohort study done in patients receiving palliative 
radiotherapy. Concurrently a second cohort was followed up by the palliative care team, 
in the palliative care service. 
Inclusion Criteria  
 All patients receiving palliative radiotherapy. 
Exclusion Criteria  
 Patients less than eighteen years of age. 
 Patients or families who decline to participate. 
 Cases where a suitable   informant   could not  be identified . 
 Cases where language or other barriers prevent adequate monthly 
telephone/postal/ clinic   follow   up. 
Pap Versus PPI 
Patients with incurable cancer who are receiving palliative radiotherapy were 
clinically assessed and scored at baseline using both the Palliative Prognostic Scale 
(PaP) and the Palliative Prognostic Index (PPI). The scoring systems classified patients 
into poor, intermediate or better prognostic groups at baseline. These scoring systems 
were based on the presence of symptoms such as dyspnoea, anorexia, oedema, the 
general performance status. A family member or contact person was contacted once a 
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month to enquire about the patient’s condition. Survival or date of death was noted 
based on this information. This enabled us to know which patients have survived less 
than 1 week, 1 month or three months. The survival data thus obtained,  was compared 
with the baseline categorization to assess and compare the sensitivity, specificity and 
positive predictive values of the PaP and the PPI. 
PaP(Palliative Prognostic Score). PaP is a scoring system developed to estimate 
the survival of terminally ill cancer patients. It was constructed by adding six variables 
which were individually predictors of survival. These variables were clinician prediction 
of survival, Karnofsky performance status, anorexia, dyspnoea, total white blood count 
and lymphocyte percentage. Patients who have not had a WBC count in the past two 
weeks will have a blood test done The PaP score is generated by applying a ‘weighted’ 
scoring system to each of these variables. Total scores range from 0 to 17.5 and 
patients were divided into three prognostic categories. The total scores for the three 
groups A,B,C were 0-5.5,5.6 -11,11.1-17.5 and the 30 days survival probabilities were 
>70%,30–70%,<30% respectively. 
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PAP SCORE 
Score Prognostic variable        
0 Dyspnoea 
  Absent 
       
1   Present        
 
0 
Anorexia 
  Absent 
       
1.5   Present        
 
0 
Karnofsky performance status 
  ≥ 50 
       
2.5 10-40        
 
 
0 
Clinician Prediction of Survival 
(weeks) 
  >12 
       
2   11-12        
2.5   7-10        
4.5   5-6        
6   3-4        
8.5   1-2        
 
0 
Total white blood cell count 
  Normal(4800-8500) cell/mm3 
       
0.5   High (850-11 000) cell/mm3        
1.5   Very high (>11 000) cell/mm3        
 
0 
Lymphocyte percentage 
  Normal (20%-40%) 
       
1   Low (12%-19.9%)        
2.5   Very low (0%-11.9%)        
Interpretation of the PaP score 
Risk group Total score 
A 0-5.5 
B 5.6-11 
C 11.1-17.5 
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PPI (PALLIATIVE PROGNOSTIC INDEX).  
Morita et al developed PPI based on five variables like performance status, oral 
intake, oedema, dyspnoea at rest and delirium which were independently predictive of 
survival and  each of these variables had a partial score (two or three).The total PPI 
score is calculated from the sum of the partialscores and could range from 0 to 15 and 
patients were divided in to three groups A,B,C with scores less than or equal to 4,more 
than 4 but less than or equal to 6,more than 6 respectively.Total score of 4 was taken 
as a cut off   and positive predictive value (PPV) for 6-week survival  and negative 
predictive value (NPV) for 6-week survivals were  0.83, 0.71 respectively. 
.Score Variable         
 
 
4 
Palliative performance scale  
(modified Karnofsky) 
  10-20 
        
2.5   30-50         
0   ≥60         
 
2.5 
Oral intake 
  Severely  reduced 
        
1.0   Moderately reduced         
0   Normal         
 
1.0 
Oedema 
  Present 
        
0.0   Absent         
 
3.5 
Dyspnoea at rest 
  Present 
        
0.0   Absent         
 
4.0 
Delirium 
  Present 
        
0.0   Absent         
 
Risk Group  Total score 
A <\=4 
B  > 4 and < or = 6 
C > 6 
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Modified PaP (MPaP) Score 
It was created by removing the blood investigations (total white blood cell and 
differential lymphocytes counts) scores from the original PaP score. 
In this there were 3 categories A,B,C with scores in the range of 0 to 5,5.1 to 7 and 7.1 
to 13.5 respectively. 
Modified PPI (MPPI) Score 
It was created by adding the partial score of Clinician Estimated Survival (CPS) 
to the original PPI score.The 3 new categories A,B,C with scores in the range of 0 to 
6,more than 6 to less than 11 and more than or equal to 11 respectively. 
Ethics approval 
The study was presented to the Institutional Review Board of the Christian 
Medical College, Vellore. 18.12.2008   and No.6728.  Data collection   was started after 
IRB approval was obtained. 
Consent 
All patients were explained about the study, the follow up and informed consent 
was obtained. 
Patients were recruited in the study from January 2009 to September 2009.  
Relatives were contacted regularly by telephone to document survival or date of death.   
 
  17
 
Statistical analysis                          
The dataset was analyzed using SPSS version 16.0. The results of the cohort 
followed up in Palliative Care are also reported here with permission. 
The cohorts were analyzed individually and together, to document the sensitivity, 
specificity, and positive predictive values of the original and modified PaP and PPI 
scores, in predicting I month and three month survival. This information was used to 
ascertain if any particular prognostic score was clearly superior in predicting survival. 
A) Sensitivity 
The sensitivity of a diagnostic test is the proportion of patients for whom the 
outcome is positive that are correctly identified by the test or the ability of a test to 
identify correctly all those who have the disease (true positives). 
Sensitivity = True positive/ (True positive +False negative) x 100. 
B) Specificity 
The specificity is the proportion of patients for whom the outcome is negative that 
are correctly identified by the test or the ability of a test to identify correctly those who 
do not have the disease (true negatives). 
Specificity =True negative /(True negative+False positive) x100. 
C) Positive Predictive Value (PPV): 
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The positive predictive value (PPV) of a test is the probability that a patient has a 
positive outcome given that they have a positive test result. This is in contrast to 
sensitivity, which is the probability that a patient has a positive test result given that they 
have a positive outcome. 
PPV=True positive/ (True positive +False positive) x 100. 
D) Negative Pre dictive Value (NPV): The negative predictive value (NPV) is the 
probability that a patient has a negative outcome given that they have a negative test 
result, in contrast to specificity, which is the probability that a patient has a negative test 
result given that they have a negative outcome[28,29] 
NPV= True negative /(True negative+False negative) x100. 
Example: 
The PPV of the test using lactate level above 1.5 mmol/l as an indicator of mortality is 
81/672 =0.12, and the NPV is 674/719 = 0.94. Therefore, 12% of patients in the sample 
whose test results were positive actually died and 94% whose test results were negative 
survived. The 95% confidence interval for PPV is 10–15% and that for NPV is 92–
96%.The prevalence of the disease will alter tha PPV and NPV. When the prevalence is 
low the PPV will be low, irrespective of the sensitivity and specificity of the test. A higher 
prevalence will always result in a raised PPV and a lowered NPV [28]. 
For a sensitivity and specificity of 90 and a d of 10:- 
   4x90x10     =   36 
         102 
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We will need at least 36 patients in each cohort who have died 1month after 
recruitment, and 36 who have lived would be needed.  To ensure this we aimed to 
recruit 200 patients in the palliative care and palliative RT categories 
E) Receiver Operating Characteristic Curve (ROC CURVES) 
ROC curves were plotted and areas under the curve compared for the different 
scores. The ROC curve is a graphical technique for assessing the ability of a test to 
discriminate between those with disease and those without disease. A graph of 
sensitivity (the true positive rate) against 1 – specificity (the false positive rate) is called 
a receiver operating characteristic (ROC) curve.A perfect test would have sensitivity and 
specificity both equal to 1. In order to construct a ROC curve we need to calculate the 
sensitivity and specicity of the test for each possible cut point value. The ROC curve 
would start at the origin (0,0),go vertically up the y-axis to (0,1) and then horizontally 
across to (1,1). A good test would be somewhere close to this ideal. The closer the 
graph gets to the upper left hand corner (0,1), the better the test is at discriminating 
between cases and non cases.  
The ROC curve may be used for three purposes: 
1. It allows the determination of the cut-off point at which optimal sensitivity 
and specificity are achieved 
2. It allows an assessment of the diagnostic accuracy of a test and  
3. It allows the comparison of the usefulness of two or more diagnostic tests.  
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The performance of a diagnostic variable can be quantified by calculating the 
area under the ROC curve (AUROC). The ideal test would have an AUROC of 1, 
whereas a random guess would have an AUROC of 0.5. The performance of a 
diagnostic variable can be quantified by calculating the area under the ROC curve 
(AUROC)[30,28,31,32].   
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F) Median survival  
Median survival is defined as The time from either diagnosis or treatment at 
which half of the patients with a given disease are found to be, or expected to be, still 
alive [33]. 
Kaplan Meir curves were plotted to compare the median survivals, with 
confidence intervals for various classifications: 1) primary diagnosis, 2) secondary 
diagnosis, 3) Pap and PPI categories, 4) KPS categories, 5) clinician prediction of 
survival 6) Clinical symptoms 7) laboratory parameters. 
G) Confidence interval: The definition of confidence interval is ‘a range of values for a 
variable of interest (the measure of treatment effect) are  constructed so that this range 
has a specified probability of including the true value of the variable. The specified 
probability is called the confidence level, and the end points of the confidence interval 
are called the confidence limits’. It is conventional to create confidence intervals at the 
95% level – so this means that 95% of the time properly constructed confidence 
intervals should contain the true value of the variable of interest. The confidence 
intervals provide a range about the observed effect size. This range is constructed in 
such a way that we know how likely it is to capture the true – but unknown – effect size 
[34,35]. 
The survival analysis provided useful clinical data about the prognosis of patients 
with advanced cancer, followed up prospectively in India. Unlike in clinical trials, these 
patients did not have to meet strict inclusion criteria, and are more likely to be 
representative of patients with incurable cancer in our country. 
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RESULTS 
                  Table 1a    DEMOGRAPHIC  DATA         
PALLIATIVE CARE COHORT 
Variables 
n % 
Age 
   18 – 39 
   40 – 59 
   60 – 80 
 
32 
96 
68 
 
16.3 
48.97 
34.9 
Gender  
   Female 
    Male 
 
123 
73 
 
62.8 
37.2 
 
 
                  Table 1 b                  
PALLIATIVE RT COHORT 
Variables 
n % 
Age 
   18 – 39 
   40 – 59 
   60 – 80 
 
20 
61 
20 
 
19.8 
60.3 
19.8 
Gender  
   Female 
    Male 
 
49 
52 
 
48.5 
51.5 
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                 Table 1c             
COMBINED COHORT 
Variables 
n % 
Age 
   18 – 39 
   40 – 59 
   60 – 80 
 
52 
157 
88 
 
17.5 
52.9 
29.6 
Gender  
   Female 
    Male 
 
172 
125 
 
57.9 
42 
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BASE LINE DIAGNOSTIC CATEGORIES 
                      
            Table  2a  
 
PALLIATIVE CARE COHORT I 
Primary diagnosis  
n 
Cervix     39 
Head andNeck   21 
Lung     10 
Breast                                                 14 
Colorectal/Oesophagus 15 
Ovary                                                 04 
Stomach                                            20 
Glioblastoma                                    02 
Gall bladder    05 
Not Known 07 
Others 22 
Secondary diagnosis  
Lung                                              10 
Bone                                            20 
Brain                                             04 
Liver                                             25 
Local recurrence 74 
Not known 16 
Others 14 
Histology  
Squamous  cell 60 
Adeno   46 
Sarcoma 05 
Others      32 
Not known    23 
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            Table  2b 
 
 
PALLIATIVE RT COHORT  
Primary diagnosis  
n 
Cervix     04 
Head andNeck   10 
Lung     21 
Breast                                                19 
Colorectal/Oesophagus 07 
Not Known  13 
Ovary and others                               16 
Secondary diagnosis  
Bone                                            48 
Brain                                             24 
Local recurrence 03 
Not known 09 
Others 09 
Histology  
Squamous  cell 13 
Adeno   40 
Sarcoma 01 
Others      37 
Not known    02 
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             Table  2c 
 
 
COMBINED COHORT 
Primary diagnosis  
n 
Cervix     43 
Head andNeck   31 
Lung     31 
Breast                                                33 
Colorectal/Oesophagus 22 
Ovary                                                05 
Stomach                                            20 
Glioblastoma                                    02 
Gall bladder    05 
Not Known 20 
Others 39 
Secondary diagnosis  
Lung                                              10 
Bone                                            68 
Brain                                             28 
Liver                                             25 
Local recurrence 77 
Not known 25 
Others 23 
Histology  
Squamous  cell 73 
Adeno   86 
Sarcoma 06 
Others      69 
Not known    25 
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                                                                      Table  3a: PROGNOSTIC CATEGORIES 
 
PALLIATIVE CARE COHORT  Variables  
n 
Modified  KPS  
 More than or equal  to 60 132 
 Between  30  and  50     50 
 Between  10  and  40                               14 
Clinician estimated survival  
More than 3  months                              79 
Between 1 and 3 months   73 
Less than or equal to 1month 44 
 
                                              Table  3b:  
 
PALLIATIVE RADIOTHERAPY 
COHORT Variables  
n 
Modified  KPS   
More than or equal  to 60 59 
Between  30  and  50  35 
 Between 10  and  40                    07 
Clinician estimated survival  
More than 3  months                     41 
Between 1 and 3 months   52 
Less than or equal to 1month 08 
 
                                            Table  3c:  
 
COMBINED COHORT Variables  
n 
 Modified  KPS  
  More than or equal  to 60 191 
  Between  30  and  50 85 
   Between  10  and  40                              21 
Clinician estimated survival  
More than 3  months                              120 
Between 1 and 3 months   125 
Less than or equal to 1month 52 
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Table 4a Accuracy of  Scores in Predicting One Month Survival :  
COHORT 3(COMBINED) – 1 MONTH 
 
 
 
 
 
Tests of significance 
 
 
 
 PaP PPI MPaP MPPI 
CLINICIAN 
ESTIMATE 
SURVIVAL 
NUMBER (n) 227 280 282 280 269 
Positive Predictive 
Value PPV 
45.5% 67.9% 55.9% 58.5% 59.1% 
Negative Predictive 
Value NPV 
82.5% 81.34% 85.2% 82.4% 78.2% 
Sensitivity 30.6% 28.8% 50% 36.4% 48.1% 
Specificity 89.9% 95.8% 88% 92.1% 91% 
Value(PaP,MPaP,PPI,MPPI) Exactsignificance(PaP,MPaP,PPI,MPPI)
Pearson 
Chi-Square 
12.997,44.036,33.869,32.597 0.001,0.000,0.000, 0.000 
Likelihood 
Ratio 
11.259,38.962,28.161,27.970 0.001,0.000,0.000, 0.000 
Fisher’Exact 
Test 
 0.001,0.000,0.000, 0.000 
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Table 4b Accuracy of  Scores in Predicting One Month Survival : 
 COHORT 1(PAL CARE) -1 MONTH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tests of significance 
 
Value(PaP,MPaP,PPI,MPPI) ExactSignificance(PaP,MPaP,PPI,MPPI)
Pearson 
Chi-Square 
13.984,43.395,35.155,32.898 0.000,0.000,0.000,0.000 
Likelihood 
Ratio 
12.758,40.619,32.288,30.216 0.001,0.000,0.000,0.000 
Fisher’Exact 
Test 
- -, 0.001,0.000,0.000,0.000 
 
 
 
 
 
 PaP PPI MPaP MPPI 
NUMBER (n) 132 185 186 185 
Positive Predictive 
Value PPV 
60.9% 82.6% 69.76% 71.8% 
Negative Predictive 
Value NPV 
77.98% 77.77 82.5% 79.1% 
Sensitivity 36.8% 34.5% 54.5% 41.8% 
Specificity 90.4% 96.9% 90.1% 93.1% 
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Table 4c Accuracy of Scores in Predicting One Month Survival :  
 COHORT 2 (PAL RT )-1 MONTH) 
 
 PaP PPI MPaP MPPI 
NUMBER (n) 95 90 96 95 
Positive Predictive 
ValuePPV 
10% 0 18.8% 11.1% 
Negative Predictive 
Value 
NPV 
82.23 87.8% 90% 88.4% 
Sensitivity 9.1% 0 27.3% 9.1% 
Specificity 89.3% 94% 84.7% 90.5% 
 
 
 
Tests of significance 
 
Value(PaP,MPaP,PPI,MPPI) Exactsignificance(PaP,MPaP,PPI,MPPI)
Pearson 
Chi-Square 
0.027,1.006,0.691,0.002 1.000,0.386,0.634,1.000 
Likelihood 
Ratio 
0.028,0.895,1.266,0.002 1.000,0.386,0.634,1.000 
Fisher’Exact 
Test 
 1.000,0.386,1.000,1.000 
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Table 4d Accuracy of  Scores in Predicting Three Month Survival : 
 COMBINED COHORT-3 MONTHS 
 
 PaP PPI MPaP MPPI CLINICIAN 
ESTIMATE 
SURVIVAL 
NUMBER (n) 217 269 271 269 259 
Positive Predictive 
Value PPV 
67.3% 78.6% 78.7% 78.2% 55.8% 
Negative Predictive 
Value 
NPV 
68.8% 56.6% 61.4% 68.9% 65.7% 
Sensitivity 67.9% 39% 52.1% 56% 76.1% 
Specificity 68.2% 88.2% 84.4% 82.7% 56% 
 
 
 
Tests of significance 
 
Value(PaP,MPaP,PPI,MPPI) ExactSignificance(PaP,MPaP,PPI,MPPI)
Pearson 
Chi-Square 
16.954,37.371,24.273,24.300 0.000,0.000,0.000,0.000 
Likelihood 
Ratio 
18.137,41.699,30.277,27.307 0.000,0.000,0.000,0.000 
Fisher’Exact 
Test 
17.847,40.802,29.001,26.708 0.000,0.000,0.000,0.000 
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Table 4e Accuracy of  Scores in Predicting Three Month Survival : 
COHORT 1 (PAL CARE)-3 MONTH. 
 
 PaP PPI MPaP MPPI 
 NUMBER (n) 123 175 176 175 
Positive Predictive 
Value PPV 
78.9% 84% 87.3% 81.9% 
Negative Predictive 
Value NPV 
59.1% 48% 53.1% 53.4% 
Sensitivity 62.5% 39.3% 50.9% 55.1% 
Specificity 76.5% 88.2% 88.2% 80.9% 
 
 
 
 
Tests of significance 
 
Value(PaP,MPaP,PPI,MPPI) Exact 
significance(PaP,MPaP,PPI,MPPI)
Pearson Chi-
Square 
6.754, 19.720, 13.273, 
14.327 
0.010, 0.000,0.000,0.000 
Likelihood Ratio 7.388, 22.905, 17.030, 
16.868 
0.010,0.000,0.000,0.000 
Fisher’Exact Test  0.010,0.000,0.000,0.000 
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Table 4f Accuracy of  Scores in Predicting Three Month Survival : 
COHORT 2(PAL RT ) 3 MONTH. 
 
 PaP PPI MPaP MPPI 
NUMBER (n) 94 94 95 94 
Positive Predictive 
Value PPV 
54% 65% 61.3% 68.9% 
Negative Predictive 
Value 
NPV 
83.7% 71.2% 76.2% 78.1% 
Sensitivity 79.4% 
 
38.2% 55.9% 58.8% 
Specificity 61% 88.1% 80% 84.7% 
 
 
 
Tests of significance. 
 
Value(PaP,MPaP,PPI,MP
PI) 
ExactSignificance(PaP,MPaP,PPI,MP
PI) 
Pearson Chi-
Square 
9.323,17.321,9.319,7.476 0.034,0.000,0.058,0.105 
Likelihood Ratio 9.141,17.085,10.673,7.295 0.013,0.000,0.006,0.037 
Fisher’Exact Test 9.317,16.715,9.810,7.657 0.006,0.000,0.006,0.012 
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ROC  CURVES 
COHORT  1 PALLIATIVE CARE . 1 MONTH ( Fig  1) 
 
 
 
Table 5a: AREA UNDER CURVE (AUC)   
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound
PaP Score .821 .037 .000 .748 .895
MOD.PAP .811 .039 .000 .734 .887
PPI Score .794 .043 .000 .711 .878
MOD_PPI .810 .041 .000 .731 .890
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COHORT 2 PALLIATIVE RADIOTHERAPY – 1 MONTH (Fig 2) 
 
Table 5b: AREA UNDER CURVE (AUC)    
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound 
PaP Score .693 .080 .038 .536 .849
MOD.PAP .652 .083 .102 .489 .815
PPI Score .604 .076 .266 .455 .752
MOD_PPI .640 .084 .132 .476 .804
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COHORT 3 COMBINED CATEGORY  -1 MONTH (Fig 3) 
 
 
 
Table 5c: AREA UNDER CURVE (AUC)   
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound 
PaP Score .780 .035 .000 .712 .849
MOD.PAP .771 .036 .000 .700 .842
PPI Score .744 .038 .000 .669 .819
MOD_PPI .770 .037 .000 .696 .843
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Fig 4 -COHORT 1 PALLIATIVE CARE . 3 MONTH    
 
 
Table 5d: AREA UNDER CURVE (AUC) 
 
 
 
 
 
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound 
PaP Score .766 .044 .000 .680 .853
MOD.PAP .765 .044 .000 .679 .851
PPI Score .755 .045 .000 .667 .843
MOD_PPI .767 .044 .000 .681 .853
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COHORT 2 PALLIATIVE RADIOTHERAPY – 3 MONTH (Fig 5) 
 
 
Table 5e: AREA UNDER CURVE (AUC)  
 
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound 
PaP Score .683 .059 .003 .567 .799
MOD.PAP .739 .056 .000 .629 .849
PPI Score .721 .057 .000 .609 .833
MOD_PPI .744 .056 .000 .634  
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Fig 6-COHORT 3 COMBINED CATEGORY - 3 MONTH 
 
.  
Table 5f : AREA UNDER CURVE (AUC)  
 Asymptotic 95% Confidence Interval 
Test Result 
Variable(s) 
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Lower Bound Upper Bound 
PaP Score .719 .035 .000 .651 .787
MOD.PAP .746 .033 .000 .680 .811
PPI Score .738 .033 .000 .673 .804
MOD_PPI .756 .033 .000 .692 .820
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 Fig 7 Survival Curves Based on KPS Category, Combined Cohort 
 
           
• KPS1: Modified KPS score 10-20. 
• KPS2:Modified KPS score  30-50. 
• KPS3:Modified KPS score more than 60. 
 
    Fig 8 Survival Curves Based on PaP Category, Combined Cohort 
 
• PaP 1:Risk group C 
• PaP 2:Risk group B 
• PaP 3:Risk group A 
  41
    
 Fig 9 Survival Curves Based on PPI Category, Combined Cohort 
 
• PPI 1:Risk group C 
• PPI 2:Risk group B 
• PPI 3:Risk group A 
 
Fig 10 Survival Curves Based on CPS Category, Combined Cohort 
 
 
• Clinician Prediction Survival 1:Survival less than or equal 1month. 
• Clinician Prediction Survival 2:Survival 1 to 3 months. 
• Clinician Prediction Survival 3:Survival more than 3 months. 
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     Fig 11 Survival Curves Based on Oral intake Category, Combined Cohort 
 
 
• Oral intake 1: Severely reduced 
• Oral intake 2: Moderately reduced. 
• Oral intake 3:Normal 
 
     Fig 12 Survival Curves Based on Dyspnoea Category, Combined Cohort 
 
• Dyspnoea 1: Present. 
• Dyspnoea 2: Absent. 
 
 Fig 13 Survival Curves Based on Delirium Category, Combined Cohort 
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•  Delirium 1: Present. 
•  Delirium 2: Absent. 
 
Fig 14 Survival Curves Based on Lymphocyte count Category, Combined Cohort 
 
 
•     Lymphocyte 1: Very low(0-11.9%). 
•     Lymphocyte 2:Low(12-19.9%). 
•  Lymphocyte 3:Normal(20-40%). 
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Table 6 a: Median Survival Based On  Diagnostic Category In Combined Cohort. 
 
 
Primary site 
 
Number(n) 
 
Median 
 
Confidence 
interval 
Mean 
 
Confidence 
interval 
Cervix 41 17.1 6.11 ,    
28.09 
16.73 12.83 ,    
20.64 
Head/neck 33 14.50 9.84 ,    
19.16 
19.44 13.75 ,    
25.13 
Lung 31 8 4.18 ,   
11.82 
15.76 10.74,     
20.78 
Colorectal 12 8.40 0.00 ,  19.05 14.14 7.81   ,    
20.47 
Breast 34 17.30 4.5  ,  30.10 20.65 15.34,    
25.96 
Unknown 19 13.30 -- 15.27 10.80 ,   
19.74 
Others 41 18.60 13.35,23.85 19.37 14.20,    
24.54 
Ovary 05 - - 10.30 5.13  ,    
15.47 
Glioblastoma 02 0.1 - 1.65 0.00,       
4.69 
Oesophagus 08 - - 22.53 12.75,    
32.31 
Gallbladder 05 9.10 1.77,  16.43 8.94 4.73,     
13.15 
Stomach 21 8.0 2.79, 13.21 11.21 6.69,     
15.74 
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Table 6b:  Mean Survival Based On  Diagnostic Category In Combined Cohort.. 
 
Secondary 
site 
Number(n) 
 
Median 
 
Confidence 
interval 
Mean 
 
Confidence 
interval 
Lung 10 8.50 -- 15.44 8.10, 22.78 
Bone 67 28 13.90, 42.10 22.96 18.97,26.94 
Brain 28 9.00 6.41, 11.59 13.28 9.54, 17.01 
Liver 25 8.00 2.45, 13.55 12.71 8.08, 17.33 
Local  
Recurrence  
75 11.30 5.25, 17.35 14.48 11.58,17.38 
Not known 17 - - 26.08 18.63, 33.52
Others 22 13.30 3.11, 23.49 15.26 10.68, 19.84
 
Table 6c:  Median Survival  Based On  Global  Assessments. 
Category CLINICIAN 
ESTIMATE 
WEEKS(m), (n) 
PaP 
(m),(CI),(n)) 
PPI 
(m),(CI),(n) 
KPS 
(m),(CI),(n) 
Worst 3.30 
(CI 1.58,5.02) 
N=42 
5.0 
(CI 3.06,6.94) 
N=28 
2.50 
(CI 1.12, 3.88) 
N=22 
5.0 
(CI 1.28,8.72). 
N=18 
Intermediate 13.0(CI 
8.33,17.67) 
N=110 
12.20(CI 
6.73,17.67) 
N=69 
7.50(CI 
0.00,15.11) 
N=39 
8.0(CI 
5.11,10.89). 
N=74 
Best Not reached Not reached  20.20(CI 
13.73,26.67) 
N=189 
20.60(CI 
14.21,26.99) 
N=160 
•  In the clinician estimation categories, confidence intervals did not overlap, 
indicating better discrimination 
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Table 6d : Mean Survival  Based On  Global  Assessments 
Category CLINICIAN 
ESTIMATE 
WEEKS(m),(CI),(n) 
PaP 
(m),(CI),(n)P  
PPI(m),(CI),(n)  KPS(m),(CI),(n)
Worst 6.40 
(CI 3.86,8.94) 
N=42 
7.27 
(CI 4.42,10.12) 
N=28 
3.67 
(CI 2.21,5.13) 
N=22 
10.13 
(CI 4.43,15.82) 
N=18 
Intermediate 17.64 
(CI 14.60,20.67) 
N=110 
15.54 
(CI 
12.10,18.98) 
N=69 
10.07 
(CI 
7.29,12.85) 
N=39 
12.27 
(CI 9.36,15.18) 
N=74 
Best 25.28 
(CI 22.23,28.34) 
N=101 
26.66 
(CI23.43,29.89)
N=106 
22.10 
(CI19.63 
,24.57) 
N=189 
22.93 
(CI20.20,25.66)
N=160 
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Table 6e:    Median Survival By Symptoms And Lab Tests(W-worst, I-intermediate ,B-best) 
MEDIAN 
SURVIVAL 
CONFIDENCE 
INTERVAL 
MEAN 
SURVIVAL 
CONFIDENCE 
INTERVAL 
W 7.30 
N=51 
4.10 , 10.50 9.15 6.92, 11.38 
I 11.20 
N=113 
6.81, 15.59 14.91 12.56, 17.27 
ORAL INTAKE 
B 
 
- 
N=87 
-- 26.66 23.15, 30.16 
W 4.40 
N=23 
0.80,8.0 8.29 4.92,11.67 DYSPNOEA 
B 15.50 
N=229 
11.22, 19.78 19.85 17.60, 22.09 
W 3.20 
N=10 
0.00,6.76  5.00 1.85,8.15 DELIRIUM 
B 14.50 
N=241 
10.20,18.80 19.48 17.29,21.66 
W 12.20 
N=71 
7.05,17.35 17.41 13.53,21.29 
I 15.00 
N=64 
6.58,23.42 15.59 12.51,18.68 
LYMPHOCYTE  
COUNT 
B 28.60 
N=67 
13.36,43.84 23.97 19.80,28.13 
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Discussion 
Patients with advanced malignancy are often referred for treatment/supportive 
care to an oncologist. Decisions regarding the type and duration of treatment need to be 
based on the possible prognosis, to avoid the errors of unwarranted treatment toxicity or 
therapeutic nihilism. Estimation of prognosis is also important for families who need to 
prioritise their personal and social goals.  
The accurate prognosis of these patients is often difficult to estimate because of 
multiple variables such as primary diagnosis, different sites of secondaries,   comorbid 
illness and rapidity of spread. The clinicians use  their past experience and medical 
knowledge to estimate the prognosis, but are not often  accurate Hence systematic  
scoring systems were developed which have been  validated in different centres in the 
world.  The use of such scoring systems has been recommeded by the European 
Association of Palliative Care [2].  
In this study we aimed to compare two available prognostic scores the Palliative 
Prognostic score (PaP) [8] and the Palliative Prognostic Index (PPI) [23] and the 
Clinician Prediction of survival for predicting one and three month survivals. The  PaP 
score is based on six variables; dyspnoea, anorexia, Karnofsky performance 
status,clinician prediction of survival,total white blood count,and lymphocyte percentage. 
The total score  ranges from 0 to 17.5 points is separated into three categories:category 
3(0-5.5 points) predicts a probability higher than 70% of at least 30 days survival 
time,category 2 (5.6-11 points) predicts a probability between 30% and 70% ,and finally 
,category 1(11.1-17.5 points) predicts a chance lower than 30% of the 1 month survival 
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time.The PaP was validated for Italian hospice-home care patients in a multicenter 
study and successfully used for patients with incurable malignancy and end stage non 
cancer illness. The PPI score does not use lab investigations, but it contains five 
variables:the performance status(modified Karnofsky scale),oral 
intake,edema,dyspnoea at rest and delirium . A performance status score lower than 
50% predicts a chance of survival of 10% for 6 months [17,27].The sum of score of the 
PPI ranges from 0 to 15 points.The scores above six points are associated with a 20% 
survival for 3 weeks ;a sum score above four points are associated with a 20% chance 
of survival for 6 weeks.The PPI was found to predict 6 week survival with a PPV of 0.91 
and a NPV of 0.67. 
We also modified the scores MPaP , MPPI after removing the lab investigations 
from the PaP and adding the Clinician Estimate of Survival to PPI respectively. 
Patient population 
There were more women than men in the palliative care cohort(Table 1b) .The 
most common primary diagnosis  was cervical malignancy (Table 2a,2c) and it was well 
correlated with the population based cancer registry datas[36].In females breast cancer 
is the second most common malignancy in females as per the Madras Metropolitan 
Tumour Registry[37]. 
The majority of the patients in the radiotherapy cohort had bone secondaries, 
(Table 2b) with breast and lung as primary diagnosis. Painful bone metastases are the 
commonest indication for palliative radiotherapy[38]. The palliative care cohort had a 
large group of patients with local recurrence of cervical and head and neck cancers. 
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(Table 2a) as these  are common primary cancers in India, and many of these patients 
were not suitable for further definitive therapy. Stomach cancer was common in the 
palliative care cohort. This is a common cancer in India [39], but not many patients are 
suitable for palliative radiotherapy, hence we found fewer patients with stomach cancer 
in the palliative RT cohort. 
Survival scores versus actual survival 
One month survival  
Combined cohort,one month survival prediction accuracy(Table4a)  
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations (p < .001) with the actual one month survival. (Table 4a, Chi 
square).28(10% )of patients  were in PPI category C (code 1)  ( with a high possibility of 
death within 1month ). Of these   19 died  within the month giving a positive predictive 
value of 67.9%.  PPI ‘s sensitivity was 28.8% because it predicted 19 out of 66 the 
actual deaths that occurred by one month. Out of the 214 patients who survived one 
month, 205 were not in category C. The specificity for the test was therefore 95.8%.  
Similarly for PAP 33(14.5%) of patients were in PaP category C (code 1)  ( with a 
high possibility of death within 1month month). Of these 15 died within the month giving 
a positive  predictive value of 45.5%.  PaP ‘s sensitivity was 30.6% because it predicted 
15 out of 49 the actual deaths that occurred by one month. Out of the 178 patients who 
survived one month, 160 were not in category C. The specificity for the test was 
therefore 89.9%. 
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The results of PPI   are similar to those  reported in the literature.The 6 weeks 
survival was predicted with a PPV of 83% and NPV of 71% in the study by Morita[23]. A 
survival of  less than 6 weeks was predicted with PPV of 91% and NPV of 64% in the 
study by Stone etal[21]. Stiel et al reported a specificity of 94% and sensitivity of 51% 
for three week survival . In the PaP   in the category C   with less than 30%  chance for 
30 days survival the   sensitivity  was  67%   and  specificity   was  100%[27]. 
Inference 
PPI had the highest specificity and PPV of all the four scores, but a low 
sensitivity. (The best sensitivity 48.1% was  in fact was for the clinician’s prediction of 
survival.). The clinician estimated survival category had sensitivity of 48.1%, specificity 
of 91%,PPV of 59.1% and NPV of 78.2%. PPI   is useful in identifying   sick patients 
since   it is simple,  It can be done easily in the home and hospice settings, and can be 
quickly scored even by relatively new clinicians. PPI does not use any lab 
investigations. It is worth noting that removing the laboratory tests did not reduce the 
predictive accuracy of PaP score at one month. But PPI has limitations it misses some 
sick patients as evidenced by its low sensitivity. Clinical predictions for individual 
patients can probably improve this as suggested by Stiel et al [27]. 
Palliative Care Cohort( Cohort 1)  
One month survival prediction accuracy (Table 4b) 
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations ( p< .001) with the actual one month survival. (Table 4b, Chi 
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square).23(12.4%) of patients were in PPI category C (code 1)  ( with a high possibility 
of death within 1month month). Of these 19 died within the month giving a positive 
predictive value of 82.6%.  PPI ‘s sensitivity was 34.5% because it predicted 19 out of 
the 55  actual deaths that occurred by one month. Out of the 130 patients who survived 
one month, 126 were not in category C. The specificity for the test was therefore 96.9%.  
Similarly for PAP 23(17.4%) of patients were in PaP category C (code 1)  ( with a 
high possibility of death within 1month. Of these 14 died within the month giving a 
positive predictive value of 60.9%.  PaP ‘s sensitivity was 36.8% because it predicted 14 
out of the 38 actual deaths that occurred by one month. Out of the 94 patients who 
survived one month, 85 were not in category C. The specificity for the test was therefore 
90.4%. 
Palliative Radiotherapy Cohort-Cohort 2 
One month survival prediction accuracy (Table 4c) 
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations (p < .001) with the actual one month survival. (Table 4c, Chi 
square).5(5.2%) of patients were in PPI category C (code 1)  ( with a high possibility of 
death within 1month month).  
Out of the total 15(both PaP and PPI) patients, only 1 had expired at one month, 
hence meaningful statistical analysis or conclusions were not possible. When clinicians 
expect a short survival of less than one month, patients may not be referred for 
palliative RT. Among the category C patients who were in this group, many fell into 
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category C because they had a poor KPS as they were immobile due to bone 
secondaries, and not because they were critically ill.  
3 months survival 
Combined cohort, three  month survival prediction accuracy (Table 4d)  
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations (p < .001) with the actual three month survival. (Table 4d, Chi 
square).There was 70(26%) of patients were in PPI category B or C  (code 1)  ( with a 
high possibility of death within 3 month). Of these 55 died within three months giving a 
positive predictive value of 78.6%.  PPI ‘s sensitivity was 39% because it predicted 55 
out of 141 the actual deaths that occurred by three months. Out of the 127 patients who 
survived three months, 112 were not in category C. The specificity for the test was 
therefore 88.2%.  
Similarly for PAP (107)49.3% of patients were in PaP category B or C  (code 1) ( 
with a high possibility of death within 3 month). Of these 72 died within three month 
giving a positive predictive value of 67.3%. PaP ‘s sensitivity was 67.9% because it 
predicted 72 out of the 106  actual deaths that occurred by 3 month. Out of the 110 
patients who survived three month, 75 were not in category C. The specificity for the 
test was therefore 68.2%. These results were similar to the results seen in the literature. 
In the PPI the sensitivity for the those with a 20% chance of 6 weeks survival was 
46% and specificity was 84% and those with more than 20% chance of 6 week survival 
had a sensitivity of 83% and specificity of 66%[ 27]. 
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Palliative care cohort(Cohort 1) Table 4e. 
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations ( p< .001) with the actual three month survival. (Table 4e) 
50(28.5%) of patients were in PPI category B or C  (code 1)  ( with a high possibility of 
death within 3 month). Of these 42 died within the month giving a positive predictive 
value of 84%.  PPI ‘s sensitivity was 39.3% because it predicted 42 out of 107 the actual 
deaths that occurred by three month. Out of the 68 patients who survived three month, 
60 were not in category C. The specificity for the test was therefore 88.2%.  
Similarly for PAP 57(46.3%) of patients were in PaP category B or C  (code 1)  ( 
with a high possibility of death within 3 month). Of these 45 died within the month giving 
a positive predictive value of 78.9%.  PaP ‘s sensitivity was 62.5% because it predicted 
45 out of  the  72 actual deaths that occurred by three month. Out of the 51 patients 
who survived three month, 39 were not in category C. The specificity for the test was 
therefore 76.5%.  
In the Palliative radiotherapy cohort (Table 4f) 
All four scores, Pap, PPI, modified Pap and Modified PPI showed highly 
significant associations (p < .001) with the actual three month survival. (Table 4f, Chi 
square).20(21.2 %) of patients were in PPI category B or C  (code 1)  ( with a high 
possibility of death within 3 month). Of  these 13 died within the  3 month giving a 
positive predictive value of 65%.  PPI ‘s sensitivity was 38.2% because it predicted 13 
out of the 34 actual deaths that occurred by three month. Out of the 59 patients who 
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survived three month, 52 were not in category C. The specificity for the test was 
therefore 88.1%.  
Similarly for PaP 50(53.2%) of patients were in PaP category B or C  (code 1)  ( 
with a high possibility of death within 3 month). Of these 27 died within the three month 
giving a positive predictive value of 54%.  PaP ‘s sensitivity was 79.4% because it 
predicted 27 out of the 34 actual deaths that occurred by three month. Out of the 59 
patients who survived three month, 36 were not in category C. The specificity for the 
test was therefore 61%.  
Inference 
Most reports from literature have not studied the accuracy of these scores in 
predicting three month survival.  In our study PPI had a good PPV and specificity- 
patients with a poor PPI score were very likely to die in three months. But its sensitivity 
was very low- it identified less than half of those who died. Estimating three month 
deaths is more difficult than one month deaths.  It is possible that   adding clinicians 
estimates and laboratory tests, may increase accuracy as compared to only symptoms 
and KPS recorded in PPI. This is reflected in the 76% sensitivity in clinician’s estimates, 
and the two thirds accuracy of Pap in terms of PPV, sensitivity, specifity and NPV. 
Removing the laboratory tests from PaP reduced its sensitivity for three month survival 
from 67.9% to 52.1%. Decisions regarding three month survivals are usually needed for 
determining whether to give longer courses of treatment. In such situations it should be 
feasible to do lab tests, and get the clinical assessment of an experienced clinician.  
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ROC curves  (Figures 1-6) 
ROC curves   were generated for all the four scores in the 1 month and more 
than 3 month survival categories in all the cohorts. (Figures 1-6). There were insufficient 
events in the palliative RT cohort at one month to draw inferences.  
In all other cases, the   areas   under curve (AUC) (Tables 5a-5f) for all these 
scores were good, and highly statistically significant.  
The AUC for the combined cohorts   PaP was 0.780 with CI 0.712 to 0.849, and 
for PPI 0.744 with CI 0.669 to 0.819 at one month. Removal of laboratory tests did not 
significantly reduce the AUC (  modified Pap AUC) at one month  . 
The AUC for the combined cohorts   PaP was 0.719 with CI 0.651 to 0.787, and 
for PPI 0.738 with CI 0.673 to 0.804 at three   month. . 
As there was overlap of the confidence intervals for these scores, no score was 
clearly superior to the above based on ROC analysis, and the choice of score can be 
based on convenience, and clinical relevance as discussed in the section on sensitivity 
and positive predictive value.   
Median survivals  
A. By primary diagnosis ( Table 6a)  
In the primary diagnostic category patients with carcinoma cervix, head and neck 
breast had higher median survivals of 17.1,14.5 and 17.3 weeks respectively. In the 
literature the median survival for metastatic carcinoma cervix was 4-9 months with 
  57
chemotherapy, relapse in nodal region had a 24 weeks survival and relapse in other 
regions had a median survival of 12 weeks.[40]. 
Shorter survivals were seen in patients with lung cancer (8 weeks,)   colorectal 
(8.4 weeks),stomach cancer (8 weeks) and carcinoma of the gall bladder( 9.1 weeks). 
As per the cancer statistics from National cancer institute the 5 year relative survival for 
metastatic lung cancer was only 2% [41]. 
 
B. By metastatic site (Table 6b) 
Patients with bone metastases  had the longest median survivals of 28 wks( CI 
13.9 to 42.10).In the RTOG trial the median survival in patients with solitary and multiple  
bone metastasis was   36 and 24 weeks respectively [42]. Patients with brain 
metastases had a median survival of  9  weeks in good comparison with the literature; 
patients in RPA class 3(KPS less than 70 ,age more than 65 years and uncontrolled 
primary tumour have median survival of 2 months[43].Patients with local recurrence had 
longer survivals than brain  metastases but shorter than  bone metastases (11.3 weeks, 
CI 5.25 to 17.35). 
C. Median survival by symptoms (  Table  6e and figures 11 to 14) 
The median survival based on the patients symptoms showed that patients who 
had dyspnoea and delirium had lowest median survival 4.4 weeks (confidence intervals 
0.8 to 8) and 3.2 weeks (confidence intervals 0.00 to 6.76).In other symptom categories 
there was considerable overlap in the confidence intervals and hence they are not as 
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reliable as dyspnoea and delirium. In the study by Morita et al the performance status 
10-20 with dyspnoea at rest and presence of delirium was associated with a survival of 
less than 3 week. In the multiple regression analysis the regression coefficients ± 
standard error for  Dyspnea at rest 0.88±0.16 and partial score was 3.5 and for Delirium 
it was 1.0 ±0.17, 4.0 respectively[23].In the study by  Pirovano  et al dyspnoea was 
independent variable with prognostic Value[8] 
 
D Median survival by global assessments 
D.1 Clinician Estimate of Survival (Table 6c,6d ,Figures 7-10) 
The Pap score needs the clinician to classify survival in two week         
increments upto  three months. Based on this prospective assessment we were able to 
catrtegorize patients into worst prognosis ( clinician estimate less than four weeks), 
intermediate prognosis (I month to less than three months) and better prognosis (more 
than 3 months). 
In the Clinician estimate survival for the combined   category,  those estimated to 
live less than four weeks  had an actual  median survival of 3.3 weeks with a 95% 
confidence interval between 1.58 and 5.02 . Those estimated to live between one to 
three months (  intermediate group) had a median survival of 13 weeks with a 95% 
confidence interval between 8.33 and 17.67.There was no overlap of the confidence 
interval and hence it was good tool discriminating these groups.In the good prognostic 
categories the median survival was not yet reached as more than 50% of patien ts were 
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still alive, but it was greater than 20 weeks.  Further follow up is   necessary to  
document  the median survival. 
D.2 PPI  
In the combined category, those estimated to live less than four weeks had an 
actual median survival of 2.5 weeks with a 95% confidence interval between 1.12 and 
3.88. Those estimated to live between one to three months ( intermediate group ) had a 
median survival of 7.50 weeks with a 95% confidence interval between 0.00 and 15.11. 
In the good prognostic categories the median survival was 20.20 weeks with a 95% 
confidence interval  between 13.73 to 26.67. 
D.3 PAP  
In the combined category, those estimated to live less than four weeks had an 
actual median survival of 5 weeks with a 95% confidence interval between 3.06 and 
6.94. Those estimated to live between one to three months   ( intermediate group) had a 
median survival of 12.2 weeks with a 95% confidence interval between 6.73 and 17.67.  
KPS  
In the combined category, those estimated to live less than four weeks had an 
actual median survival of 5 weeks with a 95% confidence interval between 1.28 and 8. 
72 . Those estimated to live between one to three months   (   intermediate group) had a 
median survival of 8 weeks with a 95% confidence interval between 5.11 and 10.89. In 
the good prognostic categories the median survival was 20.60 weeks with a 95%   
confidence   interval   between  14.21 to 26.99. 
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CONCLUSION 
1) All scores were highly statistically significant   prediction of   the survivals in the 
population studied. These tests were less specific for individual patients,   except 
those who are    very sick. 
2) Clinician estimate was as good as other scores for less than 1 month and more 3 
month categories. It had a better sensitivity compared to the PPI score. Hence 
even with availability of these scores its value should not be negligible. 
3) No score was superior to another as seen in the ROC curves.  
There was no loss of AUC by removing laboratory   investigations from the Pap 
Score for predicting on month survival  
4) PPI was a simple score and useful especially   in very sick patients, to predict 
one month survival. 
5) Three month survival prediction is possibly more accurate by incorporating lab 
tests and clinician estimates than by PPI scores alone. 
The shortest median survivals were for PPI category C. The longest were for 
patients where the clinician estimated more than three months. 
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6) Bone secondaries had the longest survival by metastatic site and many patients 
could be considered for further systemic therapy to improve survival, especially if 
they have good  Pap  or  PPI  scores. 
7) Patients with local recurrence had survivals in the range, median survival 11.3 
weeks with confidence intervals from 5.25 to 17.35. Many of these patients are 
not suitable for further radiotherapy, and it is necessary to improve the quality of 
life (QOL) through good palliative care. 
8) Patients with brain metastases, lung cancer and stomach cancer have shorter 
survivals, and decisions regarding long or expensive courses of treatment should 
be made judiciously. 
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APPENDIX I 
ROC Curve Cordinates 
Coordinates of the Curve  
Test Result 
Variable(s) 
Positive if Greater Than or 
Equal To(a) Sensitivity 1 - Specificity 
-1.00 1.000 1.000
.25 1.000 .928
.75 1.000 .916
1.25 1.000 .843
1.75 .909 .795
2.25 .909 .759
2.75 .818 .687
3.25 .818 .663
3.75 .818 .639
4.25 .818 .590
4.75 .818 .530
5.25 .818 .494
5.75 .818 .482
6.25 .818 .422
6.75 .727 .361
7.25 .727 .313
7.75 .545 .253
8.25 .364 .229
8.75 .364 .205
9.25 .364 .181
9.75 .364 .157
10.25 .273 .157
10.75 .273 .120
11.50 .091 .108
12.25 .091 .096
PaP Score 
12.75 .091 .048
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13.25 .091 .036
13.75 .091 .024
14.25 .091 .012
14.75 .000 .012
 
16.00 .000 .000
-1.000 1.000 1.000
.500 .909 .747
1.250 .909 .735
1.750 .818 .602
2.250 .818 .530
3.000 .818 .518
3.750 .727 .434
4.250 .545 .398
4.750 .455 .349
5.250 .455 .301
5.750 .455 .289
6.250 .455 .277
6.750 .364 .169
7.250 .273 .157
7.750 .273 .145
8.250 .273 .133
9.000 .091 .072
9.750 .091 .060
10.500 .091 .036
11.500 .091 .012
12.250 .000 .012
MOD.PAP 
13.500 .000 .000
-1.00 1.000 1.000
.50 .909 .711
1.50 .727 .458
2.25 .636 .458
PPI Score 
3.00 .545 .361
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3.75 .182 .265
4.25 .182 .229
4.75 .182 .205
5.50 .091 .084
6.25 .000 .060
7.00 .000 .048
7.75 .000 .036
8.25 .000 .024
9.75 .000 .012
 
12.00 .000 .000
-1.00 1.000 1.000
.50 .909 .795
1.50 .818 .639
2.25 .818 .578
2.75 .818 .530
3.25 .818 .446
3.75 .636 .434
4.25 .545 .434
4.75 .545 .373
5.25 .545 .337
5.75 .455 .313
6.25 .455 .265
6.75 .455 .241
7.25 .364 .205
7.75 .273 .145
8.25 .091 .133
9.00 .091 .120
10.00 .091 .108
10.75 .091 .096
11.50 .091 .060
13.00 .091 .048
MOD_PPI 
14.25 .091 .036
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15.25 .000 .024
16.50 .000 .012
 
18.00 .000 .000
The test result variable(s): PaP Score, MOD.PAP, PPI Score, MOD_PPI has at least 
one tie between the positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are 
the averages of two consecutive ordered observed test values.  
 
ROC Curve  
 
Coordinates of the Curve  
Test Result 
Variable(s) 
Positive if Greater Than or 
Equal To(a) Sensitivity 1 – Specificity 
-1.00 1.000 1.000
.25 1.000 .920
.75 1.000 .886
1.25 1.000 .794
1.75 .979 .754
2.25 .979 .726
2.75 .938 .651
3.25 .917 .611
3.75 .917 .589
4.25 .917 .514
4.75 .854 .457
5.25 .833 .406
5.75 .792 .394
6.25 .750 .343
6.75 .729 .309
7.25 .708 .286
PaP Score 
7.75 .667 .257
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8.25 .604 .229
8.75 .604 .206
9.25 .604 .189
9.75 .563 .149
10.25 .479 .149
10.75 .417 .120
11.25 .313 .103
11.75 .250 .086
12.25 .250 .080
12.75 .229 .051
13.25 .208 .046
13.75 .188 .034
14.25 .167 .017
14.75 .125 .017
15.25 .063 .006
16.50 .042 .006
 
18.50 .000 .000
-1.000 1.000 1.000
.500 .979 .737
1.250 .979 .697
1.750 .875 .554
2.250 .875 .503
3.000 .854 .469
3.750 .792 .389
4.250 .729 .343
4.750 .688 .309
5.250 .646 .269
5.750 .625 .257
6.250 .604 .229
6.750 .542 .166
7.250 .500 .149
MOD.PAP 
7.750 .458 .137
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8.250 .458 .126
9.000 .333 .086
9.750 .292 .069
10.250 .229 .046
10.750 .188 .046
11.500 .125 .023
12.250 .104 .023
13.000 .063 .006
 
14.500 .000 .000
-1.00 1.000 1.000
.50 .979 .743
1.25 .792 .429
1.75 .792 .423
2.25 .729 .411
3.00 .667 .314
3.75 .500 .229
4.25 .500 .206
4.75 .417 .183
5.25 .354 .080
5.75 .333 .069
6.25 .271 .046
6.75 .208 .029
7.25 .188 .029
7.75 .188 .017
8.25 .125 .011
8.75 .104 .006
9.75 .083 .006
10.75 .063 .006
11.25 .063 .000
11.75 .042 .000
13.50 .021 .000
PPI Score 
16.00 .000 .000
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-1.00 1.000 1.000
.50 .979 .794
1.25 .896 .606
1.75 .896 .600
2.25 .875 .560
2.75 .875 .509
3.25 .854 .429
3.75 .792 .400
4.25 .771 .400
4.75 .729 .360
5.25 .729 .326
5.75 .688 .303
6.25 .688 .263
6.75 .688 .246
7.25 .604 .211
7.75 .583 .171
8.25 .458 .149
8.75 .438 .137
9.25 .417 .126
9.75 .375 .097
10.25 .375 .091
10.75 .333 .086
11.50 .250 .063
12.25 .250 .051
12.75 .229 .040
13.25 .208 .040
13.75 .188 .040
14.25 .167 .029
14.75 .125 .017
15.05 .104 .017
15.55 .083 .017
MOD_PPI 
16.50 .083 .006
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17.50 .083 .000
18.25 .063 .000
19.25 .042 .000
21.75 .021 .000
 
24.50 .000 .000
The test result variable(s): PaP Score, MOD.PAP, PPI Score, MOD_PPI has at least 
one tie between the positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are 
the averages of two consecutive ordered observed test values.  
 
ROC Curve  
 
Coordinates of the Curve  
Test Result 
Variable(s) 
Positive if Greater Than or 
Equal To(a) Sensitivity 1 - Specificity 
-1.00 1.000 1.000
.25 .972 .898
.75 .972 .796
1.25 .930 .653
1.75 .915 .612
2.25 .915 .571
2.75 .845 .510
3.25 .831 .408
3.75 .817 .408
4.25 .761 .306
4.75 .690 .286
5.25 .634 .245
5.75 .592 .245
6.50 .535 .204
7.50 .521 .204
PaP Score 
8.25 .493 .163
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8.75 .479 .143
9.25 .465 .143
9.75 .408 .122
10.25 .366 .122
10.75 .324 .082
11.25 .268 .082
12.00 .211 .041
12.75 .197 .020
13.25 .183 .020
13.75 .169 .000
14.25 .127 .000
14.75 .113 .000
15.25 .056 .000
16.50 .042 .000
 
18.50 .000 .000
-1.000 1.000 1.000
.500 .930 .612
1.250 .887 .571
1.750 .775 .388
2.250 .761 .347
3.000 .718 .286
3.750 .634 .245
4.250 .577 .204
4.750 .549 .204
5.250 .507 .184
5.750 .493 .163
6.250 .451 .122
6.750 .423 .122
7.250 .380 .122
7.750 .352 .102
8.250 .338 .102
MOD.PAP 
9.000 .282 .082
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9.750 .254 .041
10.250 .197 .020
10.750 .169 .020
11.750 .113 .000
13.000 .056 .000
 
14.500 .000 .000
-1.00 1.000 1.000
.50 .972 .633
1.25 .676 .306
1.75 .676 .286
2.25 .620 .286
3.00 .507 .245
3.75 .408 .184
4.25 .408 .163
4.75 .352 .122
5.25 .296 .041
5.75 .254 .041
6.25 .211 .020
6.75 .155 .000
7.25 .141 .000
7.75 .127 .000
8.25 .085 .000
8.75 .070 .000
9.75 .056 .000
11.00 .042 .000
11.75 .028 .000
13.50 .014 .000
PPI Score 
16.00 .000 .000
-1.00 1.000 1.000
.50 .986 .653
1.25 .817 .449
MOD_PPI 
1.75 .817 .429
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2.25 .789 .408
2.75 .761 .367
3.25 .704 .327
4.00 .676 .286
4.75 .620 .286
5.25 .577 .286
5.75 .549 .265
6.25 .549 .224
6.75 .535 .224
7.25 .479 .184
7.75 .465 .184
8.25 .380 .163
8.75 .366 .143
9.25 .352 .102
9.75 .324 .041
10.25 .310 .041
10.75 .282 .041
11.50 .225 .020
12.25 .211 .020
12.75 .183 .000
13.25 .169 .000
13.75 .155 .000
14.25 .127 .000
14.75 .099 .000
15.05 .085 .000
15.55 .070 .000
17.00 .056 .000
18.25 .042 .000
19.25 .028 .000
21.75 .014 .000
 
24.50 .000 .000
The test result variable(s): PaP Score, MOD.PAP, PPI Score, MOD_PPI has at least 
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one tie between the positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are 
the averages of two consecutive ordered observed test values.  
 
 
Coordinates of the Curve  
Test Result 
Variable(s) 
Positive if Greater Than or 
Equal To(a) Sensitivity 1 - Specificity 
-1.00 1.000 1.000
.25 .971 .915
.75 .971 .898
1.25 .941 .831
1.75 .882 .780
2.25 .882 .729
2.75 .824 .644
3.25 .794 .627
3.75 .735 .627
4.25 .735 .559
4.75 .676 .508
5.25 .676 .458
5.75 .676 .441
6.25 .647 .373
6.75 .618 .288
7.25 .588 .237
7.75 .471 .186
8.25 .382 .169
8.75 .353 .153
9.25 .324 .136
PaP Score 
9.75 .324 .102
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10.25 .294 .102
10.75 .294 .051
11.50 .235 .034
12.25 .206 .034
12.75 .118 .017
13.25 .088 .017
13.75 .059 .017
14.25 .059 .000
14.75 .029 .000
 
16.00 .000 .000
-1.000 1.000 1.000
.500 .882 .712
1.250 .853 .712
1.750 .824 .525
2.250 .765 .458
3.000 .765 .441
3.750 .706 .339
4.250 .618 .305
4.750 .588 .237
5.250 .559 .186
5.750 .559 .169
6.250 .559 .153
6.750 .412 .068
7.250 .382 .051
7.750 .353 .051
8.250 .324 .051
9.000 .176 .017
9.750 .147 .017
10.500 .118 .000
11.500 .059 .000
MOD.PAP 
12.250 .029 .000
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 13.500 .000 .000
-1.00 1.000 1.000
.50 .853 .678
1.50 .735 .356
2.25 .706 .356
3.00 .618 .254
3.75 .441 .153
4.25 .412 .119
4.75 .353 .119
5.50 .206 .017
6.25 .147 .000
7.00 .118 .000
7.75 .088 .000
8.25 .059 .000
9.75 .029 .000
PPI Score 
12.00 .000 .000
-1.00 1.000 1.000
.50 .882 .780
1.50 .853 .559
2.25 .824 .492
2.75 .824 .424
3.25 .794 .322
3.75 .706 .322
4.25 .676 .322
4.75 .618 .271
5.25 .588 .237
5.75 .559 .203
6.25 .529 .153
6.75 .500 .136
7.25 .412 .119
7.75 .324 .068
MOD_PPI 
8.25 .265 .051
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9.00 .265 .034
10.00 .235 .034
10.75 .206 .034
11.50 .147 .017
13.00 .147 .000
14.25 .118 .000
15.25 .059 .000
16.50 .029 .000
 
18.00 .000 .000
The test result variable(s): PaP Score, MOD.PAP, PPI Score, MOD_PPI has at least 
one tie between the positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are 
the averages of two consecutive ordered observed test values.  
 
ROC Curve  
Coordinates of the Curve  
Test Result 
Variable(s) 
Positive if Greater Than or 
Equal To(a) Sensitivity 1 - Specificity 
-1.00 1.000 1.000
.25 .971 .907
.75 .971 .852
1.25 .933 .750
1.75 .905 .704
2.25 .905 .657
2.75 .838 .583
3.25 .819 .528
3.75 .790 .528
4.25 .752 .444
4.75 .686 .407
5.25 .648 .361
PaP Score 
5.75 .619 .352
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6.25 .571 .296
6.75 .562 .250
7.25 .543 .222
7.75 .505 .194
8.25 .457 .167
8.75 .438 .148
9.25 .419 .139
9.75 .381 .111
10.25 .343 .111
10.75 .314 .065
11.25 .257 .056
11.75 .219 .037
12.25 .210 .037
12.75 .171 .019
13.25 .152 .019
13.75 .133 .009
14.25 .105 .000
14.75 .086 .000
15.25 .038 .000
16.50 .029 .000
 
18.50 .000 .000
-1.000 1.000 1.000
.500 .914 .667
1.250 .876 .648
1.750 .790 .463
2.250 .762 .407
3.000 .733 .370
3.750 .657 .296
4.250 .590 .259
4.750 .562 .222
5.250 .524 .185
MOD.PAP 
5.750 .514 .167
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6.250 .486 .139
6.750 .419 .093
7.250 .381 .083
7.750 .352 .074
8.250 .333 .074
9.000 .248 .046
9.750 .219 .028
10.250 .171 .009
10.750 .152 .009
11.500 .095 .000
12.250 .086 .000
13.000 .038 .000
 
14.500 .000 .000
-1.00 1.000 1.000
.50 .933 .657
1.25 .695 .333
1.75 .695 .324
2.25 .648 .324
3.00 .543 .250
3.75 .419 .167
4.25 .410 .139
4.75 .352 .120
5.25 .267 .028
5.75 .238 .028
6.25 .190 .009
6.75 .143 .000
7.25 .133 .000
7.75 .114 .000
8.25 .076 .000
8.75 .057 .000
9.75 .048 .000
PPI Score 
10.75 .038 .000
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11.25 .029 .000
11.75 .019 .000
13.50 .010 .000
 
16.00 .000 .000
-1.00 1.000 1.000
.50 .952 .722
1.25 .829 .509
1.75 .829 .500
2.25 .800 .454
2.75 .781 .398
3.25 .733 .324
3.75 .686 .306
4.25 .676 .306
4.75 .619 .278
5.25 .581 .259
5.75 .552 .231
6.25 .543 .185
6.75 .524 .176
7.25 .457 .148
7.75 .419 .120
8.25 .343 .102
8.75 .333 .083
9.25 .324 .065
9.75 .295 .037
10.25 .286 .037
10.75 .257 .037
11.50 .200 .019
12.25 .190 .009
12.75 .171 .000
13.25 .162 .000
13.75 .152 .000
MOD_PPI 
14.25 .124 .000
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14.75 .086 .000
15.05 .076 .000
15.55 .067 .000
16.50 .048 .000
17.50 .038 .000
18.25 .029 .000
19.25 .019 .000
21.75 .010 .000
 
24.50 .000 .000
The test result variable(s): PaP Score, MOD.PAP, PPI Score, MOD_PPI has at least 
one tie between the positive actual state group and the negative actual state group.  
a The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are 
the averages of two consecutive ordered observed test values.  
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Appendix II    Format for Obtaining Verbal Consent 
We are doing a research study to help us to better understand the clinical course of our 
patients, based on their physical problems.  
If you and your relative are willing, one of our staff will phone once a month to find out 
about the patient’s condition.  
For patients who have not had a recent WBC count about 2 ml of blood be taken for 
these tests.   
You and your relative are free to refuse to take part in the study, or to withdraw at any 
time. If you have any questions regarding the study you may contact Dr 
Abraham.Phone -9442314682. 
                                                   
 
 
  88
 
  89
Appendix  III - EAPC RecommendationsR 
Recommendation 1 
In advanced cancer patient management, physicians should base their decisions about 
therapeutic interventions and settings of care considering both 
quality of life and life expectancy (grade D) 
An accurate prognostication of life expectancy will facilitate decision making both for 
professional careers and for patients and their families (grade D) 
Recommendation 2 
The clinical prediction of survival is a valid tool to obtain a general prognostic evaluation 
of patients (grade A), but it is subject to a series of factors 
that limits its accuracy (see text); its use is recommended together with other prognostic 
factors (grade A) 
Recommendation 3 
Clinicians can use a number of clinical signs and symptoms that have proven to be 
associated with life expectancy in this patient population: 
performance status (grade B), cancer anorexia-cachexia syndrome signs and 
symptoms (grade B), dyspnea (grade B), and cognitive failure or 
delirium (grade B) 
Recommendation 4 
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Clinicians can use some laboratory variables associated with life expectancy: 
leukocytosis (grade B), lymphocytopenia (grade B), and high C-reactive 
protein (grade B). 
The need for a blood sample should be balanced with the clinical advantage that is 
envisaged and never taken lightly (grade D) 
Recommendation 5 
Clinicians can make use of some easily applicable prognostic scores to make a rapid 
prediction capable of identifying classes of patients with 
significantly different life expectancies (grade A) 
At the moment, the Palliative Prognostic Score is the more readily available system 
including most of the factors (grade A) 
Recommendation 6 
Establishing a prognosis is part of the therapeutic alliance; patients have the right to be 
informed or not to be informed about their prognosis 
Using and communicating prognostic information should be within the context of a 
comprehensive, individualized, patient-centered approach  
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Appendix   IV   The Karnofsky and ECOG Performance Status Scales and  
Palliative Performance Scale (PPSV2) 
                                                                                                                                                                            PALLIATIVE 
PERFORMANCE SCALE 
                                       
KARNOFSKY 
PERFORMANCE 
STATUS SCALE 
                          
EASTERN 
COOPERATIV
E  
ONCOLOGY 
GROUP 
PERFORMAN
CE STATUS 
       
PPS 
LEVEL
  
AMBULATION
                    
ACTIVITY 
AND 
EVIDENCE 
OF 
DISEASE 
                
SELF-CARE 
     
INTAKE
  
CONSCIOUS
LEVEL 
 
100%  
 
 
Full 
Normal 
activity and 
work; no 
evidence 
of disease 
Full Normal Full 
 
90% 
                     
Full 
Normal 
activity and 
work; some
evidence of 
disease 
Full Norma Full 
 
80% 
                         
Full 
Normal 
activity with
effort; 
some 
evidence of 
disease 
Full Normal 
or 
reduced
Full 
 
70% 
        Reduced Unable to 
do normal 
job/work; 
significant 
disease 
Full Normal 
or 
reduced
Full 
     
60% 
        Reduced Unable to 
do hobby/ 
house 
work; 
significant 
disease 
Occasional 
assistance 
necessary 
Normal 
or 
reduced
Full or 
confusion 
 50%   
 
            Mainly 
sit/Lie 
Unable to 
do any 
work; 
extensive 
disease 
Considerable 
assistance 
required 
Normal 
or 
reduced
Full or 
confusion 
                           
100%:Asymptomatic 
  
90%: Few signs or 
symptoms 
 
80%: Normal activity, 
more signs and 
symptoms 
 
70%: Capable of self-
care but not normal 
activity 
 
60%: Capable of most 
selfcare, 
requires help with 
some activities 
 
50%: Requires 
frequent assistance 
and medical care 
 
40%: Disabled 
 
30%: Severely 
disabled,hospitalization 
indicated 
 
20%: Very sick, 
urgently 
requiring 
hospitalization 
 
 
10%: Moribund 
 
 
0: Asymptomatic 
  
1: Symptomatic 
but capable 
of full self-care, 
ambulatory 
 
 
 
2: Symptomatic, 
in bed or chair 
<50% of the 
time;not able to 
work 
 
3: In bed or chair 
>50% of the 
time, not 
bedbound,but 
requires 
assistance with 
some ADL 
 
4: Bedbound 
  
 
5: Dead 
  40%             
Mainlyin bed 
Unable to 
do most 
activity; 
extensive 
disease 
            
Mainly 
assistance 
Normal 
or 
reduced
Full or 
drowsy 
+/- confusion 
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30% Totally bed 
bound 
Unable to 
do any 
activity; 
extensive 
disease 
                  
Total care 
Normal 
or 
reduced
Full or 
drowsy 
+/- confusion 
20% Totally bed 
bound 
Unable to 
do any 
activity; 
extensive 
disease 
               
Total care 
Minimal 
to 
sips 
               Full 
or drowsy 
+/- confusion 
10% Totally bed 
bound 
Unable to 
do any 
activity; 
extensive 
disease 
                
Total care 
Mouth 
care 
only 
Drowsy or 
coma,+/- 
confusion 
 
0%: Dead 
 
0%               
Death 
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Appendix  V-Proforma 
 
 
 
